Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alternol is a **natural small molecule** isolated from the fermentation of a mutant fungus, *Alternaria alternata* var. *monosporus*, found in Taxus brevifolia bark. It exhibits **broad-spectrum anti-cancer activity** by inducing reactive oxygen species (ROS), causing cell cycle arrest and apoptosis specifically in cancer cells, largely sparing non-cancerous cells[1][2][4]. Key mechanisms involve activation of xanthine oxidase (leading to ROS accumulation), interaction with mitochondrial ATP-producing proteins (resulting in ATP depletion), and induction of both intrinsic and extrinsic apoptotic pathways—including upregulation of death receptor 5 (DR5) via CHOP transcription factor activation and JNK pathway, as well as downregulation of antiapoptotic proteins (such as XIAP, survivin, Bcl-2, Mcl-1)[2]. Preclinical studies confirm efficacy in various cancer cell lines and animal xenograft models, with a favorable safety profile and high therapeutic index[1][2][3][4]. Alternol also promotes differentiation in melanoma cells by upregulating enzymes like tyrosinase, TRP-1, and TRP-2[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alternol.